Kolexia
Simonneau Gérald Pneumologie
Simonneau Gérald
Pneumologie
Hôpital Cognacq-Jay
Férolles-Attilly, France
450 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hypertension artérielle Hypertension pulmonaire Hypertension artérielle pulmonaire Hypertension artérielle pulmonaire primitive familiale Maladie chronique Embolie pulmonaire Maladies pulmonaires Sclérodermie systémique Cardiopathies

Collaborateurs

Voir plus
Humbert Marc
Humbert Marc
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Sitbon Olivier
Sitbon Olivier
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Jais Xavier
Jais Xavier
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Montani David
Montani David
Hôpital Bicêtre, Le Kremlin-Bicêtre, France

Industries

Voir plus
MSD
20 collaboration(s)
Dernière en 2023
Bayer
11 collaboration(s)
Dernière en 2022
Janssen
4 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
CHEST-1: Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Essai Clinique (Bayer)   03 novembre 2023
PATENT-1: Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Essai Clinique (Bayer)   03 novembre 2023
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept.
The European respiratory journal   02 novembre 2023
CHEST-2: Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Essai Clinique (Bayer)   02 novembre 2023
PATENT-2: Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Essai Clinique (Bayer)   02 novembre 2023
Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study.
American journal of respiratory and critical care medicine   23 octobre 2023
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.
The Lancet. Respiratory medicine   14 août 2023
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH): A Multi-centre, Multinational, Open-label, Single-dose Acute Hemodynamic Study Followed by Multi-centre, Multinational, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy (Proof-of-concept) of ACT-293987 (NS-304) in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over
Essai Clinique (Actelion)   11 août 2023
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors
Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, 12–14 June 2023, Limoges, France   07 juin 2023
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
Giornale italiano di cardiologia (2006)   03 avril 2023